Patients with Crohn’s disease who continued advanced therapies in the months before elective colorectal surgery faced a lower risk of anastomotic leak and organ space surgical site infection, according to a study published on Wednesday in the Journal of the American College of Surgeons.
The retrospective analysis covered 1,150 patients across 24 centers participating in the American College of Surgeons NSQIP-Inflammatory Bowel Disease Collaborative between 2021 and 2024. These findings challenge the previous assumption that immunosuppressive drugs should be halted prior to operations due to wound-healing fears.
After researchers adjusted for baseline differences, anastomotic leak or organ space surgical site infection occurred in 2.43% of patients who received advanced therapy. By comparison, those who did not receive these treatments experienced a 6.46% complication rate.
“The previous school of thought was if a patient needs surgery, you need to stop advanced therapies beforehand, because there was concern that they would be associated with worse outcomes including weakened wound healing or anastomotic leaks,” said Nicholas C. Neel, MD, a surgery resident and researcher at the University of California San Diego.
Among the 1,150 total participants evaluated in the cohort, 740 patients—representing 64%—received advanced therapy within 60 days before their procedures. The primary outcome measured both anastomotic leaks and organ space surgical site infections within a 30-day window.
Statistical adjustments using inverse probability of treatment weighting revealed an absolute risk difference of -4.03%. Firth penalized logistic regression demonstrated a concordant association with an odds ratio of 0.46.

Researchers noted no statistically significant differences between the two groups regarding superficial surgical site infections, deep incisional surgical site infections, or wound dehiscence. Point estimates consistently favored advanced therapy across all examined subgroups.
| Complication Type | Advanced Therapy Group | No Advanced Therapy Group |
|---|---|---|
| Anastomotic Leak or Organ Space Infection | 2.43% | 6.46% |
| Superficial Surgical Site Infection | Not Significant | Not Significant |
| Wound Dehiscence | Not Significant | Not Significant |
Anti-TNF agents made up 46% of the administered advanced therapies. Anti-IL-23 treatments followed at 33%, while anti-integrin agents accounted for 12% of the medication regimens.
“It was interesting that no matter how we sliced the data, there seemed to be a signal associated with the use of advanced therapies and some better outcomes,” Neel said.
The study concentrated exclusively on elective surgeries where medical teams could optimize patients beforehand. Urgent or emergent procedures proceeded irrespective of the patient’s current medication status.
The study authors emphasize that the observed outcomes are associative rather than directly pharmacologic. They suggest the lower complication rates likely stem from superior disease control, reduced systemic inflammation, and improved mucosal healing.
The research team called for validation through larger datasets with adequate statistical power for drug-class-specific adjusted analyses. Co-authors on the paper include Nicole Raclin, MD, Dong-Jin “Eastern” Kang Sim, PhD, and Samuel Eisenstein, MD, FACS, writing on behalf of the NSQIP-IBD Collaborative.
The study tracked a lower incidence of anastomotic leaks and organ space surgical site infections among patients who maintained their medication schedules.
The retrospective cohort analysis utilized patient data collected from 24 medical centers participating in the American College of Surgeons NSQIP-Inflammatory Bowel Disease Collaborative.
The authors stressed that the findings are strictly associative and require confirmation in larger datasets equipped for drug-class-specific adjusted analyses.
Whether these findings will prompt formal updates to preoperative medication guidelines across all surgical centers remains undetermined until larger datasets provide drug-class-specific confirmations.
Related reading